Koledokolitiasis

01Pathophysiology

Choledocholithiasis refers to the presence of gallstones within the common bile duct. The vast majority of cases are secondary, meaning the stones originally form in the gallbladder and then migrate through the cystic duct into the CBD. A smaller proportion are primary CBD stones, which form directly within the duct itself, typically composed of brown calcium bilirubinate pigment and associated with biliary stasis, bacterial colonization, or parasitic infections such as Clonorchis sinensis or Opisthorchis viverrini.

The pathophysiology begins with the same lithogenic bile that drives gallstone formation: supersaturation of bile with cholesterol, decreased bile salt concentration, and gallbladder hypomotility. Once a stone enters or forms within the CBD, it creates a mechanical obstruction to bile flow. This obstruction increases intraluminal pressure proximal to the stone, leading to ductal dilation.

Because bile can no longer drain freely into the duodenum, conjugated bilirubin accumulates in the blood, producing jaundice and scleral icterus. The conjugated bilirubin is water-soluble and filtered by the kidneys, resulting in dark (tea-colored) urine. Meanwhile, the absence of bilirubin reaching the intestine means stercobilinogen is not produced, leading to acholic (pale, clay-colored) stools. The deposition of bile salts in the skin causes pruritus.

The cholestatic pattern on laboratory testing, marked by disproportionately elevated ALP and GGT relative to transaminases, reflects biliary epithelial injury and impaired bile secretion rather than hepatocellular damage. Transaminases may be mildly elevated due to back-pressure hepatocyte injury, but the dominant finding remains cholestatic.

If the obstruction is not relieved, two dangerous complications can develop. First, stagnant bile becomes a culture medium for ascending bacterial infection, producing acute cholangitis. Second, if the stone impacts at the ampulla of Vater, it can obstruct the pancreatic duct simultaneously, triggering acute gallstone pancreatitis.

02Classification and Clinical Manifestation

03Diagnostic Workup

The diagnostic approach to choledocholithiasis is driven by pretest probability stratification. Every patient with suspected biliary obstruction should first undergo liver function tests and a transabdominal ultrasound. The ultrasound is the best initial test because it is non-invasive, widely available, and highly sensitive for detecting CBD dilation, which serves as an indirect sign of obstruction. However, the ultrasound has limited sensitivity for directly visualizing stones within the CBD, particularly in the distal duct where bowel gas interferes.

Based on the combination of clinical presentation, lab results, and ultrasound findings, the patient is stratified into low, intermediate, or high probability categories for CBD stones.

Patients with high probability (CBD dilation on ultrasound plus a visible CBD stone, or concurrent cholangitis) should proceed directly to ERCP, which is the gold standard and most accurate test. ERCP allows simultaneous diagnosis and treatment through sphincterotomy and stone extraction.

Patients with intermediate probability (abnormal LFTs with CBD dilation but no visible stone, or age over 55 with abnormal LFTs alone) should undergo MRCP or EUS before ERCP. These non-invasive tests serve as a gatekeeping step to avoid unnecessary ERCP and its associated risks. EUS is slightly more sensitive for small stones (under 5 mm), while MRCP provides better overall anatomic mapping.

Patients with low probability should proceed to cholecystectomy with intraoperative cholangiography if clinical suspicion persists, rather than pre-operative biliary imaging.

A critical testing pearl: if the patient presents with concurrent cholangitis (Charcot triad or Reynolds pentad), the priority shifts from diagnosis to emergent biliary decompression via ERCP. Do not delay with MRCP or EUS in a septic patient.

04Management and Treatment

The cornerstone of treatment is ERCP with endoscopic sphincterotomy and stone extraction. During this procedure, a side-viewing endoscope is advanced into the duodenum, and the ampulla of Vater is cannulated. A sphincterotomy is performed to widen the biliary orifice, and stones are removed using a balloon catheter or retrieval basket. The success rate for stone clearance exceeds 90 percent.

For uncomplicated choledocholithiasis without signs of infection, ERCP is performed on a semi-elective basis. The patient should receive nothing by mouth for at least 6 to 8 hours before the procedure. Post-ERCP, the most feared complication is post-ERCP pancreatitis, which occurs in 3 to 7 percent of cases. Prophylactic rectal indomethacin (100 mg) is administered immediately before or after the procedure to reduce this risk. Temporary pancreatic duct stenting is another preventive measure in high-risk patients.

When cholangitis is present, the timeline compresses. The patient must receive hemodynamic stabilization with IV fluids and empiric broad-spectrum antibiotics targeting gram-negative enteric organisms and anaerobes. Antibiotic regimens include piperacillin-tazobactam 3.375 g IV every 6 hours or a combination of a fluoroquinolone (ciprofloxacin 400 mg IV every 12 hours) with metronidazole (500 mg IV every 8 hours). ERCP for biliary decompression should occur within 24 to 48 hours. In cases of septic (Reynolds pentad) cholangitis with hemodynamic instability, emergent decompression is required.

After successful stone clearance, elective laparoscopic cholecystectomy should be performed within 2 to 4 weeks. The gallbladder is the source of the stones in secondary choledocholithiasis, and leaving it in place results in a recurrence rate of up to 25 percent within 2 years. In patients with gallstone pancreatitis, cholecystectomy should ideally occur during the same hospitalization once the pancreatitis has resolved, to prevent readmission with recurrent events.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose points on choledocholithiasis questions is by confusing the diagnostic pathway with the therapeutic pathway. A vignette describing a patient with RUQ pain, jaundice, and mildly elevated ALP may tempt you to jump straight to ERCP, but ERCP is only the first-line step when the pretest probability is high (visible CBD stone on ultrasound, cholangitis, or bilirubin over 4 mg/dL with a dilated duct). For intermediate-probability patients, the correct next step is MRCP or EUS, not ERCP. Ordering ERCP too early exposes the patient to unnecessary procedural risk, and that is exactly the reasoning the question is testing.

Another common trap involves distinguishing choledocholithiasis from cholangitis. Both originate from CBD stones, but the addition of fever transforms the diagnosis into cholangitis and changes the management priority from elective workup to emergent decompression plus antibiotics. If the vignette includes fever and rigors alongside jaundice and RUQ pain, the answer is cholangitis, not uncomplicated choledocholithiasis.

Watch for Courvoisier sign as a discriminator. A palpable, nontender gallbladder in a jaundiced patient suggests malignant obstruction (pancreatic head cancer or cholangiocarcinoma), not stone disease. In choledocholithiasis, the gallbladder is chronically inflamed and fibrotic from prior stone disease, so it does not distend and is not palpable. This is a classic board differentiator.

Finally, do not forget the post-procedural step. After successful ERCP with stone clearance, the exam will frequently ask about the next step in management. The answer is cholecystectomy, not observation. Leaving the gallbladder in situ means the stone factory remains operational, and recurrence rates are unacceptably high. In the setting of gallstone pancreatitis, cholecystectomy should be done during the same admission, not scheduled as an outpatient procedure weeks later. This sequencing question is heavily tested.